RRM2 and renal cell carcinoma: Although we explicitly elucidated that IKBKE induces RCC progression and sunitinib resistance through the RRM2-AKT pathway, which can be suppressed by CYT387, an IKBKE inhibitor, there are still a few issues to be studied.